Abstract Library

#3971 Clinical manifestation and aggressiveness of duodenopancreatic neuroendocrine tumors (DP-NET) in patients with MEN1 syndrome: A possible role of exon 2 mutations in menin gene

Introduction: Multiple endocrine neoplasia type 1 (MEN1) is a rare syndrome characterized by co-occurrence of primary hyperparathyroidism (PH), duodenopancreatic neuroendocrine tumors (DP-NET) and/or pituitary adenomas without an established genotype-phenotype correlation.

Conference:

Presenting Author: Benevento E

Authors: Benevento E, Liccardi A, Minotta R, Cannavale G, Di Iasi G,

Keywords: Multiple endocrine neoplasia type 1 (MEN1), exon two, genomic, primary hyperparathyroidism, duodenopancreatic neuroendocrine tumor, DP-NET, pituitary adenomas,

#3662 Nothing but NET? Neuroendocrine tumors in multiple endocrine neoplasia 4

Introduction: Multiple endocrine neoplasia 4 (MEN4) is a rare multi-neoplasia syndrome caused by a germline pathogenic variant in CDKN1B gene, encoding p27, a cell-cycle regulator. MEN4 manifestations include primary hyperparathyroidism (PHPT), pituitary adenomas (PitAd), and neuroendocrine neoplasms (NEN). The characteristics of MEN4-NENs have not been thoroughly characterized thus far.

Conference:

Presenting Author:

Authors: Halperin R, Arnon L, Nasirov S, Friedensohn L, Gershinsky M,

Keywords: MEN4, CDKN1B, lifetime risk, genotype-phenotype, multiple endocrine neoplasia,

#3490 Effects of radiation therapy for somatotropic pituitary adenomas depending on age

Introduction: Despite the fact that medical therapy is effective in controlling somatotropinomas, radiation therapy (RT) is still offered as a valuable choice as a treatment for pituitary adenomas.

Conference:

Presenting Author:

Authors: Issaeva S, Khalimova Z, Khokimboeva M, Davronova N,

Keywords: radiation therapy, somatotropinomas, age, growth hormone,

#3047 Functional Consequence of β-Arrestin 1 Gene Knock-Out in Pancreatic Neuroendocrine Tumor Cell Line BON-1

Introduction: An important limiting factor influencing treatment efficacy of neuroendocrine tumors (NETs) with somatostatin analogs (SSA) is the availability of somatostatin receptors (SSTR) on NETs. While downregulation or altered pattern of SSTR expression are important considerations, receptor internalization/desensitization by β-arrestins may be a crucial contributing factor. Interestingly, our previous study showed a preferential higher expression of β-arrestin 1 (ARRB1), in gastroenteropancreatic NETS (GEP-NETs) compared to pituitary adenomas.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Iyer A

Authors: Iyer A, Vriens J, Dogan-Oruç F, van Koetsveld P, Hofland L,

Keywords: β-arrestin 1, CRISPR-Cas9, BON-1, knock-out, SSTR, SSA, Pan-NET,

#2227 Screening Benefits in MEN1-Associated Pituitary Adenomas

Introduction: MEN1 is an autosomal-dominant syndrome characterized by tumors of the parathyroid glands (95%), endocrine pancreatic-gastroenteric tract (40%), and pituitary gland (30%).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Chiloiro S

Authors: Chiloiro S, Iannachero A, Giampietro A, Bianchi A, Tartaglione T,

Keywords: Pituitary adenoma,